東曜藥業-B(01875.HK):有關TAB014的臨牀研究及商業化專項被列入中國重大新藥創制科技重大專項
格隆匯1月2日丨東曜藥業-B(01875.HK)宣佈,於2020年1月2日,集團收到中國國家衞生健康委醫藥衞生科技發展研究中心的通知,其有關TAB014的臨牀研究及商業化專項被列入重大新藥創制科技重大專項。
董事會相信,此認可彰顯了集團在創新藥物開發方面的實力。作為抗血管內皮細胞生長因子單克隆抗體(抗VEGFmAb),TAB014為基於貝伐珠單抗的抗體,用於治療視網膜新生血管形成,如濕性年齡相關黃斑變性(wAMD)。TAB014亦可用於治療糖尿病黃斑水腫(DME)、視網膜靜脈阻塞(RVO)及脈絡膜新生血管(CNV),具有廣泛應用空間。TAB014於中國註冊為第1類新藥,已招募患者進行第I期臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.